Breast cancer is a major health problem. affecting one in nine women in western countries. A particularly important goal is the early identification of poor-risk patients who may benefit from aggressive intervention with intensive chemotherapy.
While many tumour factors. including hormone receptor status. ploidy and growth fraction. and the expression of various oncogenes and proto-oncogenes by the tumour cells have been proposed as prognostic indicators. the results, to date. have been equivocal in a number of instances. Recent investigations into the role of amplification of the c-erbB-2 gene. the product of which is a transmembrane protein with extensive homology to the epidermal growth factor (EGF) receptor. have also appeared to give somewhat contradictory results. Gene amplification and increased c-erbB-2 expression have been reported in approximately 20% of patients with primary breast cancer (Clark & McGuire. 1991) . Both gene amplification and increased expression of the gene product have been associated with a poorer prognosis in some studies. The discriminant power may. however. be confined to specific subsets of patients. Moreover. in a number of studies the prognostic significance of c-erbB-2 expression appears to be lost 5 or more years from diagnosis.
There has also been considerable interest, of late. in soluble forms of cell-surface receptors. Circulating soluble receptors include soluble forms of the insulin receptor and of the interleukin 2 receptor. Serum levels of soluble interleukin 2 receptor (IL-2R) can be shown to correlate with disease activity in autoimmune disorders (Rubin & Nelson. 1990) and with tumour bulk in certain lymphomas. A soluble. 100 kDa. c-erbB-2 fragment has been detected in the serum and effusions of patients with breast cancer (Mori et al.. 1990 : Leitzel et al.. 1992 and may provide prognostic information in this disease.
We have undertaken a study of 79 patients with both early-and advanced-stage breast cancer in an attempt to evaluate the prognostic significance of elevations of serum soluble c-erbB-2. Tables I and II. Serum soluble c-erbB-2 Serum levels of the soluble fraction of c-erbB-2 ranged from 2 to 278 with a mean of 35 ± 57.6 u ml-'. Intra-and interassay variation was <2%. Intra-patient variation of serum c-erbB-2 levels, when levels were tested in blood samples from 17 patients who had clinically stable disease and who had two or more separate blood samples taken at intervals of 14 to <42 days, was also <2%.
Materials and methods

Methods
Thirty-nine patients (49%) had serum soluble c-erbB-2 levels of > 10 u ml-'. (Table II) .
There was no correlation between the presence of raised serum soluble c-erbB-2 level and any specific site of relapse.
Tissue c-erbB-2 immunostaining Twenty-four patients had contemporaneous tumour tissue and serum samples available for c-erbB-2 determination. Tis- (Figure 1 ). The prognostic impact of soluble c-erbB-2 on survival was lost when the analysis was confined to ER-positive patients. possibly because of the low number of such patients. NS. not significant.
c-erbB-2 IN SERUM CORRELATES WITH BREAST CANCER STAGE
Response to therapy Serum soluble c-erbB-2 had no influence on response to either initial (P = 0.64) or salvage treatment for stage IV disease (P = 0.78).
Discussion
The c-erbB-2 protein is a 185 kDa transmembrane protein with tyrosine kinase activity. It comprises both an extracellular and an intracellular domain. While the extracellular domain has ligand-binding activity, the ligand has yet to be clearly defined (Maguire & Green, 1989) , but is thought to act as a growth factor (Perez et al., 1993) . Antibodies to c-erbB-2 have been shown to inhibit both anchorage-dependent and anchorage-independent growth in vivo (Xu et al., 1993) . c-erbB-2 has been found to be amplified in 20-30% of primary breast cancers, and gene amplification correlates with oncoprotein overexpression. c-erbB-2's impact on prognosis is. however, somewhat controversial. A number of investigators have reported a correlation between c-erbB-2 amplification and survival in node-positive primary breast cancer (Tandon et al., 1989; Borg et al., 1990) . However, both Zhou et al. (1989) and Toikkanen et al. (1992) (1992) found a highly significant correlation between disease-free survival and c-erbB-2 expression. but only in specific subsets of patients (small tumour size, ER positive and no significant in situ component), so-called 'low-risk patients'. Furthermore. while Gusterson et al. (1992) found c-erbB-2 immunostaining to have an overall prognostic impact only in patients with nodepositive disease. c-erbB-2-positive, node-negative patients receiving adjuvant chemotherapy fared less well in their study than those who were c-erbB-2 negative. These findings tended to suggest that. whatever influence the presence of c-erbB-2 expression has on the biology of breast cancer. this effect is confined to the earlier clinical phases of the illness.
In addition, it has been suggested that c-erbB-2 amplification and protein expression correlate both with poor histological grade and lack of ER expression (Cline et al., 1987; Schroeter et al., 1992) . Poller et al. (1991) demonstrated that overexpression of c-erbB-2 is significantly correlated with S-phase and proliferative index in ductal carcinoma in situ (P = 0.001), as well as in early invasive duct carcinoma (P = 0.04).
There is also evidence to suggest that c-erbB-2 overexpression may be preferentially associated with certain histological subtypes of breast cancer. Van de Vijver et al. (1988) described a high incidence of c-erbB-2 overexpression in largecell, comedo-type ductal carcinoma in situ as compared with invasive ductal carcinoma, suggesting either that the invasive ductal carcinomas that are c-erbB-2 positive are derived from a specific type (large-cell comedo) of ductal carcinoma in situ or that c-erbB-2 expression may be lost during tumour invasion and progression. Evidence supporting the first theory is provided by Maguire et al. (1992) , who found that while tumours with c-erbB-2-negative in situ components had immunonegative invasive components, tumours with immunopositive comedo-type in situ components had immunopositive invasive ductal carcinoma. It should be pointed out. however. that the immunostaining was frequently more intense in the in situ components than in the invasive carcinomas.
Soluble forms of the c-erbB-2 protein have been reported in the serum of patients with breast cancer, and in addition have been shown to correlate with disease bulk as well as with tissue overexpression in an animal model (Langton et al.. 1991) . No reports have, however, been published to date on the prognostic significance of soluble c-erbB-2 in patients with breast cancer.
The present study examined a group of 79 women with advanced breast cancer. The method used in this study measured a 100 kDa c-erbB-2 antigen fragment. which is not detected in the serum of normal controls or in patients with benign breast disease (Teramoto et al., 1991) . A surprisingly high frequency of elevated serum soluble c-erbB-2 levels was found. possibly because this study included mainly patients with aggressive disease. with 25 patients presenting with advanced breast cancer and all but five of the remainder having progressed to stage IV disease. In addition, there was a statistically significantly higher incidence of seropositivity in patients given chemotherapy as first-line therapy for progressive disease -indicative of the perception that these patients were suffering from aggressive disease. In addition. the presence of serum soluble c-erbB-2 fragment concentrations of >10 u ml' had a significant impact on overall survival from diagnosis of metastatic disease.
The lack of correlation between seropositivity and tissue expression of c-erbB-2 raises some interesting possibilities. While the lack of correlation may be due to low sample number, definite tissue staining was demonstrated in 10 of the 24 patients with tumour samples available for examination. This frequency was, again, a relatively high rate of c-erbB-2 expression. While it may be argued that lack of tissue immunostaiing is related to the sensitivity of the method, both tissue-positive and serum-ngetaive as well as tissue-negative and serum-positive cases were found. Among the serum soluble c-erbB-2-negative patients with negative tissue expression there were three patients with extremely high serum levels (range 120-160 u ml') and with extensive disease. while all four patients with negative serum soluble c-erbB-2 tissue and positive tissue staining demonstrated strong positive staining and also had extensive disease. Since both the serum and tissue assays were performed using a monoclonal antibody specific for the external domain of c-erbB-2. these findings suggest the possibility that loss of tissue expression may result from proteolytic cleavage, with release of the external domain and transfer into the blood. rendering the tissue negative to reaction with the antibody used, or that the serum component represents an alternatively spliced variant lacking the membrane domain. This question will be addressed in future studies by using antibodies to both the internal domain as well as to the external domain of the c-erbB-2 molecule.
Whatever the pathophysiological explanation. assay for soluble c-erbB-2 in serum is a relatively simple test. requiring only a blood sample rather than tissue. Soluble c-erbB-2 may offer prognostic information with seropositivity being a predictor of shorter survival in patients with breast cancer.
